• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗在预防走私和假冒伪劣卫生用品方面面临的挑战。

The challenges associated with the prevention of smuggling and counterfeiting health goods in Iran.

机构信息

Department of Health Management, Policy, and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Department of Global Health & Public Policy, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

BMC Public Health. 2024 Jun 11;24(1):1564. doi: 10.1186/s12889-024-18637-0.

DOI:10.1186/s12889-024-18637-0
PMID:38862992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11165840/
Abstract

BACKGROUND

Smuggling health goods given the importance and critical nature of health services should be undeniably addressed and controlled by all countries. This issue is especially more widespread in developing countries with more damaging consequences. This paper therefore aims to identify and analyze the challenges of preventing smuggling of health goods in Iran.

METHOD

Within this qualitative study, we conducted face-to-face, semi-structured interviews with 30 purposefully recruited key informants and stakeholders in the detection, prevention, and combating of health goods smuggling. Each interview was analyzed thematically, using an inductive approach to generate codes, then categorized and presented in the form of main themes and sub-themes. Maxqda 11 assisted in coding, analysis, and data management.

RESULTS

Three main themes emerged representing the challenges of prevention of smuggling in Iran in the areas of anti-smuggling policy development, including categories of inefficient policy and plan, and failure to reach agenda; policy implementation; categorized into actors, resources and instruments, and implementation guarantee; and finally monitoring and evaluation; including, procedures and practices, and the role of surveyors.

CONCLUSION

Prevention of smuggling health goods proves to be a highly complex, challenging, and multi-faceted practice. Therefore, strengthening policy-making, regulatory frameworks, and facilitation functions about smuggling, counterfeiting, and corruption should be promoted in parallel.

摘要

背景

鉴于卫生服务的重要性和关键性质,走私卫生用品无疑应受到所有国家的关注和控制。在发展中国家,这一问题更为普遍,其后果更为严重。因此,本文旨在确定和分析伊朗在预防卫生用品走私方面所面临的挑战。

方法

在这项定性研究中,我们对 30 名有目的地招募的、在卫生用品走私检测、预防和打击方面的关键信息者和利益攸关方进行了面对面的半结构式访谈。采用归纳法对每个访谈进行主题分析,生成代码,然后归类为主要主题和子主题。Maxqda 11 用于辅助编码、分析和数据管理。

结果

出现了三个主要主题,代表了伊朗在反走私政策发展方面预防走私的挑战,包括分类为政策效率低下和计划失败,以及未能达到议程;政策执行;分为行为者、资源和手段以及执行保障;最后是监测和评估;包括程序和实践以及检查员的作用。

结论

预防卫生用品走私被证明是一项高度复杂、具有挑战性和多方面的实践。因此,应同时加强打击走私、假冒和腐败的决策制定、监管框架和便利化功能。

相似文献

1
The challenges associated with the prevention of smuggling and counterfeiting health goods in Iran.伊朗在预防走私和假冒伪劣卫生用品方面面临的挑战。
BMC Public Health. 2024 Jun 11;24(1):1564. doi: 10.1186/s12889-024-18637-0.
2
Economic barriers to prevent the smuggling of health goods in Iran.伊朗防止卫生用品走私的经济壁垒。
BMJ Glob Health. 2024 Jun 5;9(6):e015090. doi: 10.1136/bmjgh-2024-015090.
3
A policy context and process analysis to implement the Paris Agreement on climate change in the health system of Iran.在伊朗卫生系统实施《巴黎气候变化协定》的政策背景与过程分析
BMC Public Health. 2025 Mar 6;25(1):893. doi: 10.1186/s12889-025-22029-3.
4
Exploring policy processes against microbial threats in Iran: a qualitative policy analysis.探索伊朗应对微生物威胁的政策过程:一项定性政策分析
BMJ Open. 2025 Jan 4;15(1):e087868. doi: 10.1136/bmjopen-2024-087868.
5
Drivers of vulnerability to medicine smuggling and combat strategies: a qualitative study based on online news media analysis in Iran.药物走私脆弱性的驱动因素和应对策略:基于伊朗网络新闻媒体分析的定性研究。
BMC Health Serv Res. 2024 Mar 27;24(1):383. doi: 10.1186/s12913-024-10805-7.
6
Oral health policymaking challenges in Iran: a qualitative approach.伊朗口腔健康政策制定面临的挑战:定性研究。
BMC Oral Health. 2020 Jun 1;20(1):158. doi: 10.1186/s12903-020-01148-w.
7
Challenges in adopting health technology assessment for evidence-based policy in Iran: a qualitative study.伊朗在采用卫生技术评估以制定循证政策方面面临的挑战:一项定性研究。
J Health Popul Nutr. 2025 Apr 23;44(1):134. doi: 10.1186/s41043-025-00887-2.
8
Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis.伊朗的药品补贴政策:利益相关者定性分析。
Health Res Policy Syst. 2021 Dec 23;19(1):150. doi: 10.1186/s12961-021-00762-6.
9
Banning shisha smoking in public places in Iran: an advocacy coalition framework perspective on policy process and change.伊朗公共场所禁止水烟吸食:基于倡导联盟框架对政策过程与变革的视角分析
Health Policy Plan. 2017 Jul 1;32(6):835-846. doi: 10.1093/heapol/czx015.
10
Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.发展中国家与不合格药品和假药相关的问题:一篇关于自由市场经济中抗逆转录病毒药物时代假药全球影响的综述文章。
East Afr J Public Health. 2008 Dec;5(3):205-10. doi: 10.4314/eajph.v5i3.39004.

引用本文的文献

1
Actor-network and stakeholder analysis in preventing health goods smuggling in Iran.伊朗预防卫生用品走私中的行动者网络与利益相关者分析
Global Health. 2025 Sep 1;21(1):52. doi: 10.1186/s12992-025-01147-y.

本文引用的文献

1
CRIMINAL OFFENCES RELATED TO ILLICIT TRAFFICKING IN FALSIFIED MEDICINES: INVESTIGATION PROBLEMS.非法贩卖假药相关刑事犯罪:调查问题。
Wiad Lek. 2023;76(5 pt 1):992-1000. doi: 10.36740/WLek202305116.
2
Implementing pharmaceutical track-and-trace systems: a realist review.实施药品追踪系统:一项现实主义综述。
BMJ Glob Health. 2021 May;6(Suppl 3). doi: 10.1136/bmjgh-2020-003755.
3
Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.在追求全民健康覆盖的同时维持药品质量面临的挑战:来自印度尼西亚的定性分析
BMJ Glob Health. 2021 May;6(Suppl 3). doi: 10.1136/bmjgh-2020-003663.
4
Monitoring, reporting and regulating medicine quality: tensions between theory and practice in Tanzania.药品质量监测、报告与监管:坦桑尼亚理论与实践之间的矛盾
BMJ Glob Health. 2021 May;6(Suppl 3). doi: 10.1136/bmjgh-2020-003043.
5
Perspectives of pharmaceutical stakeholders on determinants of medicines accessibility at the primary care level.制药行业利益相关者对基层医疗层面药品可及性决定因素的看法。
J Egypt Public Health Assoc. 2021 Jan 13;96(1):1. doi: 10.1186/s42506-020-00062-x.
6
Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community.南部非洲发展共同体成员国中不合标准和伪造医疗产品事件的预防、检测及应对。
J Pharm Policy Pract. 2020 Oct 20;13:71. doi: 10.1186/s40545-020-00257-9. eCollection 2020.
7
What Makes a National Pharmaceutical Track and Trace System Succeed? Lessons From Turkey.是什么让国家药品追溯系统取得成功?来自土耳其的经验教训。
Glob Health Sci Pract. 2020 Sep 30;8(3):431-441. doi: 10.9745/GHSP-D-20-00084.
8
How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?在新冠疫情时代,我们如何打击假冒药品?
Am J Trop Med Hyg. 2020 Oct;103(4):1360-1363. doi: 10.4269/ajtmh.20-0903.
9
Counterfeit drugs and medical devices in developing countries.发展中国家的假冒药品和医疗器械。
Res Rep Trop Med. 2014 Apr 24;5:11-22. doi: 10.2147/RRTM.S39354. eCollection 2014.
10
Substandard and Falsified Antibiotics and Medicines against Noncommunicable Diseases in Western Cameroon and Northeastern Democratic Republic of Congo.喀麦隆西部和刚果民主共和国东北部的非传染性疾病用劣药和假药
Am J Trop Med Hyg. 2020 Aug;103(2):894-908. doi: 10.4269/ajtmh.20-0184. Epub 2020 May 7.